Best peptides for hair growth

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex discovered in 1973 by biochemist Loren Pickart. His laboratory found that older human liver tissue exposed to GHK-Cu produced proteins more characteristic of younger tissue — a finding that launched over five decades of continuous research into this peptide's regenerative properties. The molecule consists of three amino acids (glycine, histidine, lysine) bound to a copper(II) ion, and it occurs naturally in human plasma, saliva, and urine. In young adults, circulating GHK-Cu levels average approximately 200 ng/mL. By age 60, those levels decline to roughly 80 ng/mL — a reduction of more than 60% that correlates with visible signs of aging and diminished tissue repair capacity (PMID: 35083444). GHK-Cu is one of the most broadly studied peptides in the research literature, with effects documented across skin, lung, bone, liver, stomach, and nervous system tissue. Gene profiling studies using the Broad Institute Connectivity Map have identified over 4,000 human genes whose expression changes in response to GHK-Cu treatment, making it one of the most broadly active gene modulators among known bioactive peptides (PMID: 26236730). Key pathways with direct experimental confirmation include collagen synthesis, DNA repair, antioxidant defense, inflammatory signaling, and cellular senescence — though not all 4,000+ gene changes have been individually validated beyond the computational profiling. The strongest evidence clusters around four areas: skin regeneration and anti-aging (with collagen synthesis data dating to 1988), wound healing (across multiple tissue types), lung protection and COPD reversal (four separate studies demonstrating gene expression normalization in diseased lung tissue), and gene modulation (three major reviews covering the 4,000+ gene dataset). A 2025 study extended the research into gastrointestinal health, demonstrating GHK-Cu's ability to alleviate ulcerative colitis in mice through the SIRT1/STAT3 pathway (PMID: 40672369). In the cancer research context, GHK-Cu presents a paradox that warrants caution. While it promotes angiogenesis (blood vessel growth) — which could theoretically support tumor growth — a computational gene expression screen (Connectivity Map) of 1,309 bioactive compounds found that GHK was one of only two whose transcriptional profile reversed a 54-gene metastatic signature in colorectal cancer (PMID: 20143136). This reflects gene expression pattern matching, not direct anti-cancer testing, and no follow-up cancer model studies have been published since 2010. Individuals with active or suspected cancer should consult their oncologist before using GHK-Cu. GHK-Cu is available in multiple delivery formats. Topical serums and creams (typically 1-3% concentration) represent the most common and well-studied application, with decades of published human data supporting skin improvements. Injectable GHK-Cu provides systemic delivery at higher tissue concentrations but relies primarily on animal and in vitro evidence for most indications. Microneedling combined with topical GHK-Cu has emerged as a popular middle-ground approach, with research showing that microneedle-treated skin absorbs significantly more peptide than intact skin alone. GHK-Cu is also known by its cosmetic industry name, Copper Tripeptide-1 (INCI designation). Its chemical structure naturally occurs within the alpha 2(I) chain of type I collagen, suggesting that the body releases GHK-Cu at wound sites through proteolytic breakdown of damaged collagen — a built-in mechanism for initiating local repair (PMID: 3169264). The regulatory landscape for GHK-Cu differs between topical and injectable forms. Topical copper peptide products are classified as cosmetics and remain widely available over the counter. Injectable GHK-Cu was placed on the FDA's Category 2 list in September 2023, restricting compounding. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 Category 2 peptides would be reclassified back to Category 1 — GHK-Cu is on that list. As of March 2026, the formal FDA list update has not yet been published, with implementation expected through mid-2026. GHK-Cu has never been FDA-approved as a drug for any indication, and injectable use remains an off-label prescription through compounding pharmacies. GHK-Cu is not on the WADA prohibited list.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein found naturally in human gastric juice. First isolated and characterized by researcher Predrag Sikiric and his team at the University of Zagreb in the early 1990s, BPC-157 has become one of the most extensively studied peptides in preclinical research, with over 100 published studies investigating its effects across multiple organ systems. The compound earned the nickname "the Wolverine peptide" in biohacking communities due to the breadth of tissue repair observed in animal studies. Research spanning more than three decades has documented effects on tendons, ligaments, muscles, bones, skin, corneas, the gastrointestinal tract, liver, and nervous system in preclinical models. A 2025 systematic review published in HSS Journal (PMID: 40756949) analyzed 36 studies conducted between 1993 and 2024, finding that BPC-157 consistently improved outcomes across musculoskeletal injury models. Despite this extensive preclinical evidence, human clinical data remains extremely limited. As of March 2026, only three small human studies have been published: a 2-person intravenous safety pilot (PMID: 40131143), a small retrospective knee pain study, and a 12-patient interstitial cystitis pilot. The knee pain study reported significant relief in most participants at 6-12 months, and the cystitis pilot reported substantial symptom improvement. Neither of these smaller studies has been published with full peer-reviewed PMIDs. A Phase I safety trial (NCT02637284) was registered by PharmaCotherapia but the sponsor never published results, raising transparency concerns in the research community. BPC-157 is classified as a research compound and is not FDA-approved for any human use. In 2023, the FDA placed BPC-157 in Category 2 of its list of bulk drug substances under evaluation for compounding, meaning it does not meet safety criteria for pharmacy compounding. The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited substances list in 2022 under the S0 category (non-approved substances). Despite these regulatory designations, BPC-157 continues to be widely discussed in peptide research communities and functional medicine circles. The compound is available in injectable and oral forms. Most preclinical research has used subcutaneous or intraperitoneal injection, though studies have also demonstrated activity when administered orally, particularly for gastrointestinal conditions. An important distinction exists between the acetate salt and arginate salt forms. The arginate form reportedly demonstrates significantly better oral bioavailability and stability, though head-to-head bioavailability studies have not been published in peer-reviewed journals. A comprehensive preclinical safety evaluation published in Regulatory Toxicology and Pharmacology (PMID: 32334036) tested BPC-157 across multiple species including mice, rats, rabbits, and dogs. The study found no test-related adverse effects in single-dose or repeated-dose toxicity evaluations, no genetic toxicity, and no embryo-fetal toxicity at doses up to 20 mg/kg over six weeks. However, the absence of large-scale human safety trials means that the long-term safety profile in humans remains unknown. The primary mechanisms through which BPC-157 appears to exert its effects involve the promotion of angiogenesis, modulation of nitric oxide synthesis through multiple pathways, upregulation of growth factor receptors, and interaction with the dopamine and serotonin neurotransmitter systems. These mechanisms have been documented across dozens of studies spanning multiple research groups. BPC-157 occupies a unique position in the peptide landscape. Its broad preclinical evidence base across tissue types, combined with the near-total absence of human clinical trials, creates a significant gap between what animal research suggests and what has been demonstrated in people. All information on this page reflects published research and is presented for educational purposes only.

TB-500 is a synthetic version of Thymosin Beta-4 (Tb4), a naturally occurring 43-amino-acid protein that constitutes 70-80% of all beta-thymosins in the human body (PMID: 36464872). While the name "TB-500" is sometimes described as a fragment, most commercial TB-500 products contain the full 43-amino-acid Thymosin Beta-4 sequence. The key active region is the actin-binding domain (amino acids 17-23, the sequence LKKTETQ), which is responsible for promoting cell migration, angiogenesis, and tissue repair — the properties that have driven research interest since the early 2000s. Thymosin Beta-4 was originally isolated from the thymus gland in 1981 and initially studied for its role in immune function. Researchers later discovered broader tissue repair properties, leading to the foundational dermal wound study (PMID: 12581423) which demonstrated accelerated wound closure through enhanced cell migration, collagen deposition, and new blood vessel formation in animal models. This established the mechanistic rationale for all subsequent TB-500 research. The only published human clinical trials for Thymosin Beta-4 are in ophthalmology. RegeneRx Biopharmaceuticals developed RGN-259, a topical eye drop formulation containing 0.1% Thymosin Beta-4, which completed two Phase 2 randomized controlled trials for dry eye disease. The first trial in severe dry eye patients including those with graft-versus-host disease showed a 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining versus placebo (PMID: 25826322). A second trial in 72 subjects showed a 27% reduction in discomfort scores described as safe and well tolerated (PMID: 26056426). Note: primary endpoints in the second trial did not reach significance, though secondary endpoints showed improvement. Effects from the first trial persisted 28 days after treatment ended. Three subsequent Phase 3 dry eye trials (ARISE-1, -2, -3) did not meet their pre-specified co-primary endpoints, though secondary endpoints showed some statistical significance in pooled analyses. Cardiac repair represents the most researched preclinical application. Multiple animal studies demonstrate that Thymosin Beta-4 protects cardiac tissue after myocardial infarction by reducing oxidative damage, inhibiting fibrosis, and promoting new blood vessel formation (PMID: 35712678, 34335970). RegeneRx developed a clinical program for acute myocardial infarction treatment and completed Phase 1 safety protocols, but Phase 2 cardiac trial results were never published and the program appears to have stalled. Hair growth is another well-researched preclinical area. Mouse studies show that Thymosin Beta-4 overexpression leads to faster hair re-growth, higher hair shaft counts, and follicle clustering through P38/ERK/AKT/VEGF signaling pathways (PMID: 26083021). A 2021 review confirmed that exogenous Tb4 accelerates hair follicle cycle transitions and promotes migration of hair follicle stem cells (PMID: 33393222). No human hair growth trials have been published. A 2024 pharmacokinetic study introduced a finding that may reframe understanding of how TB-500 works: the metabolite Ac-LKKTE — not the parent TB-500 molecule — showed significant wound repair activity in vitro (PMID: 38382158). This suggests TB-500's reported effects in earlier studies may have been driven by its metabolic breakdown products rather than the intact peptide. Thymosin Beta-4 also demonstrates potent anti-fibrotic properties. It prevents fibrosis across multiple organ systems in animal models, and its N-terminal fragment Ac-SDKP can not only prevent but reverse established fibrosis in liver, lung, heart, and kidney tissue (PMID: 36580759). TB-500 is not FDA-approved for any indication. The FDA classified it as a Category 2 compound, restricting it from compounding pharmacy preparation. In February 2026, the Department of Health and Human Services announced plans to potentially reclassify certain peptides including Thymosin Beta-4, which could affect future regulatory accessibility. TB-500 is prohibited by the World Anti-Doping Agency (WADA) at all times as a Non-Specified Substance under category S2 (Peptide Hormones, Growth Factors, and Related Substances), with first-offense violations carrying a four-year ban. The U.S. Department of Defense has adopted WADA categories, making TB-500 prohibited for all military personnel. Despite its research-only status, TB-500 has been widely used in veterinary medicine, particularly in equine practice for soft tissue injuries — one of the earliest real-world applications that drove interest in human research. The combination of TB-500 with BPC-157, commonly called the "Wolverine Stack" in peptide communities, is one of the most discussed recovery-focused protocols, though no published studies have tested this combination in humans or animals.

Thymosin Beta-4 is the full-length naturally occurring protein from which TB-500 is derived. It plays a central role in tissue repair, cell migration, and immune modulation.

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered the mildest and most selective GHRP with fewer side effects than alternatives.